FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226282795> ?p ?o ?g. }

• W4226282795 abstract "The high mutation rate of COVID-19 and the prevalence of multiple variants strongly support the need for pharmacological options to complement vaccine strategies. One region that appears highly conserved among different genera of coronaviruses is the substrate-binding site of the main protease (Mpro or 3CLpro), making it an attractive target for the development of broad-spectrum drugs for multiple coronaviruses. PF-07321332, developed by Pfizer, is the first orally administered inhibitor targeting the main protease of SARS-CoV-2, which also has shown potency against other coronaviruses. Here, we report three crystal structures of the main protease of SARS-CoV-2, SARS-CoV, and Middle East respiratory syndrome (MERS)-CoV bound to the inhibitor PF-07321332. The structures reveal a ligand-binding site that is conserved among SARS-CoV-2, SARS-CoV, and MERS-CoV, providing insights into the mechanism of inhibition of viral replication. The long and narrow cavity in the cleft between domains I and II of the main protease harbors multiple inhibitor-binding sites, where PF-07321332 occupies subsites S1, S2, and S4 and appears more restricted than other inhibitors. A detailed analysis of these structures illuminated key structural determinants essential for inhibition and elucidated the binding mode of action of the main proteases from different coronaviruses. Given the importance of the main protease for the treatment of SARS-CoV-2 infection, insights derived from this study should accelerate the design of safer and more effective antivirals. IMPORTANCE The current pandemic of multiple variants has created an urgent need for effective inhibitors of SARS-CoV-2 to complement vaccine strategies. PF-07321332, developed by Pfizer, is the first orally administered coronavirus-specific main protease inhibitor approved by the FDA. We solved the crystal structures of the main protease of SARS-CoV-2, SARS-CoV, and MERS-CoV that bound to the PF-07321332, suggesting PF-07321332 is a broad-spectrum inhibitor for coronaviruses. Structures of the main protease inhibitor complexes present an opportunity to discover safer and more effective inhibitors for COVID-19." @default.
• W4226282795 created "2022-05-05" @default.
• W4226282795 creator A5017206665 @default.
• W4226282795 creator A5021870687 @default.
• W4226282795 creator A5027332054 @default.
• W4226282795 creator A5032568029 @default.
• W4226282795 creator A5040292972 @default.
• W4226282795 creator A5049692788 @default.
• W4226282795 creator A5052606983 @default.
• W4226282795 creator A5052883326 @default.
• W4226282795 creator A5054425359 @default.
• W4226282795 creator A5076318012 @default.
• W4226282795 creator A5080834198 @default.
• W4226282795 creator A5080947810 @default.
• W4226282795 creator A5083160871 @default.
• W4226282795 creator A5084058732 @default.
• W4226282795 date "2022-04-27" @default.
• W4226282795 modified "2023-09-30" @default.
• W4226282795 title "Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332" @default.
• W4226282795 cites W2008811126 @default.
• W4226282795 cites W2027484375 @default.
• W4226282795 cites W2119119130 @default.
• W4226282795 cites W2200668708 @default.
• W4226282795 cites W2255243349 @default.
• W4226282795 cites W2605364764 @default.
• W4226282795 cites W3001897055 @default.
• W4226282795 cites W3002539152 @default.
• W4226282795 cites W3003217347 @default.
• W4226282795 cites W3003668884 @default.
• W4226282795 cites W3004280078 @default.
• W4226282795 cites W3005775246 @default.
• W4226282795 cites W3011701533 @default.
• W4226282795 cites W3015608194 @default.
• W4226282795 cites W3020300207 @default.
• W4226282795 cites W3023464695 @default.
• W4226282795 cites W3046385872 @default.
• W4226282795 cites W3081918364 @default.
• W4226282795 cites W3095906208 @default.
• W4226282795 cites W3111372677 @default.
• W4226282795 cites W3125283837 @default.
• W4226282795 cites W3165497123 @default.
• W4226282795 cites W3183900570 @default.
• W4226282795 cites W3189646261 @default.
• W4226282795 cites W3192665011 @default.
• W4226282795 cites W3203986310 @default.
• W4226282795 cites W3206993253 @default.
• W4226282795 cites W4206327522 @default.
• W4226282795 doi "https://doi.org/10.1128/jvi.02013-21" @default.
• W4226282795 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35389231" @default.
• W4226282795 hasPublicationYear "2022" @default.
• W4226282795 type Work @default.
• W4226282795 citedByCount "29" @default.
• W4226282795 countsByYear W42262827952022 @default.
• W4226282795 countsByYear W42262827952023 @default.
• W4226282795 crossrefType "journal-article" @default.
• W4226282795 hasAuthorship W4226282795A5017206665 @default.
• W4226282795 hasAuthorship W4226282795A5021870687 @default.
• W4226282795 hasAuthorship W4226282795A5027332054 @default.
• W4226282795 hasAuthorship W4226282795A5032568029 @default.
• W4226282795 hasAuthorship W4226282795A5040292972 @default.
• W4226282795 hasAuthorship W4226282795A5049692788 @default.
• W4226282795 hasAuthorship W4226282795A5052606983 @default.
• W4226282795 hasAuthorship W4226282795A5052883326 @default.
• W4226282795 hasAuthorship W4226282795A5054425359 @default.
• W4226282795 hasAuthorship W4226282795A5076318012 @default.
• W4226282795 hasAuthorship W4226282795A5080834198 @default.
• W4226282795 hasAuthorship W4226282795A5080947810 @default.
• W4226282795 hasAuthorship W4226282795A5083160871 @default.
• W4226282795 hasAuthorship W4226282795A5084058732 @default.
• W4226282795 hasBestOaLocation W42262827952 @default.
• W4226282795 hasConcept C107824862 @default.
• W4226282795 hasConcept C142462285 @default.
• W4226282795 hasConcept C142724271 @default.
• W4226282795 hasConcept C159047783 @default.
• W4226282795 hasConcept C181199279 @default.
• W4226282795 hasConcept C182220744 @default.
• W4226282795 hasConcept C2522874641 @default.
• W4226282795 hasConcept C2776714187 @default.
• W4226282795 hasConcept C2777648638 @default.
• W4226282795 hasConcept C2777691041 @default.
• W4226282795 hasConcept C2779134260 @default.
• W4226282795 hasConcept C2781143361 @default.
• W4226282795 hasConcept C2993143319 @default.
• W4226282795 hasConcept C3008058167 @default.
• W4226282795 hasConcept C524204448 @default.
• W4226282795 hasConcept C54355233 @default.
• W4226282795 hasConcept C55493867 @default.
• W4226282795 hasConcept C70721500 @default.
• W4226282795 hasConcept C71924100 @default.
• W4226282795 hasConcept C86803240 @default.
• W4226282795 hasConceptScore W4226282795C107824862 @default.
• W4226282795 hasConceptScore W4226282795C142462285 @default.
• W4226282795 hasConceptScore W4226282795C142724271 @default.
• W4226282795 hasConceptScore W4226282795C159047783 @default.
• W4226282795 hasConceptScore W4226282795C181199279 @default.
• W4226282795 hasConceptScore W4226282795C182220744 @default.
• W4226282795 hasConceptScore W4226282795C2522874641 @default.
• W4226282795 hasConceptScore W4226282795C2776714187 @default.
• W4226282795 hasConceptScore W4226282795C2777648638 @default.
• W4226282795 hasConceptScore W4226282795C2777691041 @default.

• next